Surrogate biomarkers are biological indicators used to substitute for a clinical endpoint. In the context of cancer, these biomarkers can help in predicting the response to therapy, disease progression, and overall patient prognosis. They are not direct measures of clinical outcomes but are used because they can be measured more easily or earlier.
